Sartorius Stedim Biotech Shares Break Through €228.40 for the Third Time
The bioprocessing specialist gains in mid-session, in a nearly stable Paris market. The stock returns to a technical threshold it had already approached earlier this week, while analysts continue to closely monitor its valuation.
A €228.40 Threshold Breached After Several Attempts, With €230 in Sight
Shares of Sartorius Stedim Biotech gain 1.87% to €228.40, placing the stock among the strongest gainers in the SBF 120, while the index is nearly flat.
During the session, the stock moved above its €228.40 resistance and is holding just above that level. The level had already been touched on November 12, before a 2% pullback, and then approached on the 16th. This is therefore a third attempt within a few sessions.
The next level is at €230. The gap with the moving averages has widened: the price is 2.58% above the MM20 (€222.65) and nearly 24% above the MM200 (€184.51), after a 25.8% gain over three months.
Solid Nine-Month Results and Confirmed Targets Behind the Stock's Rebound
When the first nine months of 2026 were published on October 22, the group had confirmed its annual targets. Free cash flow rose 58.5%, and operating activity grew 7.8% at constant exchange rates. Management then stated that momentum across all regions clearly strengthened its confidence for the end of the year.
Among the risks cited on that occasion was the evolution of trade policy, which plays an increasingly important role in the sector.
According to the consensus of recorded analysts, the stock trades at about 45.9 times earnings for the current fiscal year and 37.7 times those of the following year. Analyst opinions therefore remain a benchmark for assessing the valuation, as the price tests €230.